Blockade of the IL-1β receptor improves hyperglycemia, beta cell function, and reduces markers associated with inflammation in T2D individuals, suggesting that IL-1β plays a role in T2D (14). This evidence concerns the gene IL1B and type 2 diabetes mellitus.